Related Experiment Video
Updated: Jun 24, 2026
08:18
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)
Published on: December 26, 2015
Clinical trials in multiple sclerosis: current and future requirements - potential pitfalls.
1Multiple Sclerosis Society of Canada, Research Chair, Division of Neurology - University of British Columbia, 2211 Wesbrook Mall, Vancouver BC, V6T 2B5, Canada. prieckmann@brain.ubc.ca
Journal of Neurology
|March 21, 2009
Summary
Early treatment for relapsing multiple sclerosis (MS) with immunomodulators shows promise, but current therapies are insufficient. New strategies are urgently needed to reduce MS-related damage and enhance tissue repair for better patient outcomes.
Area of Science:
- Neuroimmunology
- Neurology
- Clinical Therapeutics
Background:
- Relapsing multiple sclerosis (MS) treatment often begins with immunomodulatory drugs like beta-interferons or glatiramer acetate.
- Positive Phase III trial results support early intervention, even in patients with clinically isolated syndrome (CIS).
- Current disease-modifying therapies demonstrate partial effectiveness, with patients still experiencing relapses and progression.
Purpose of the Study:
- To highlight the urgent need for more effective therapeutic strategies in multiple sclerosis.
- To emphasize the goals of reducing neurological damage, protecting tissue, and enhancing repair in MS.
- To underscore the necessity of appropriate study designs for evaluating relevant outcomes in MS treatment.
Main Methods:
- Review of current evidence supporting early immunomodulatory treatment for relapsing MS.
- Analysis of Phase III trial outcomes for beta-interferons and glatiramer acetate.
- Discussion of the limitations of existing therapies and the need for novel approaches.
Main Results:
- Existing immunomodulatory treatments for MS offer partial efficacy.
- Treatment-refractory MS can rapidly lead to irreversible neurological disability.
- There is a significant unmet need for advanced therapeutic strategies in MS management.
Conclusions:
- More effective and safer drugs are required to manage MS.
- Developing improved therapeutic strategies is crucial for reducing MS-related disability.
- Robust study designs are essential to accurately assess the impact of new MS treatments.
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...